Darodipine
Names | |
---|---|
Preferred IUPAC name
Diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | |
Other names
4-(2,1,3-Benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
| |
Identifiers | |
3D model (
JSmol ) |
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C19H21N3O5 | |
Molar mass | 371.393 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Darodipine is an experimental
The longterm effect of darodipine was tested in the rats and it shows that there is no significant change in their body and brain weight values but, there is a significant change in their alkaline phosphate reactive capillary profile values. Alkaline phosphate enzymes plays an important role in the functioning of the cerebral capillary activities.[3] The effect of darodipine on plasma concentration was also tested on a group of healthy male human volunteers. The result showed that darodipine resulted in the change in heart rate and diastolic blood pressure which is related to the plasma concentration.[4]
Darodipine (50–500 nM), the sensitivity of DMPO‐COO.− adduct decreased by more than that of the DMPO‐OH adduct and the concentration-dependent drop in signal intensity. It has additional preventive effects, because of its calcium antagonistics, against free-radical mediated electrophysiological alterations; it is likely because of the trapping of such radical molecules.
See also
- Isradipine, a structural isomer of darodipine
References
Further reading
- Matucci R, Ottaviani MF, Barbieri M, Cerbai E, Mugelli A (December 1997). "Protective effect of darodipine, a calcium antagonist, on rat cardiomyocytes against oxygen radical-mediated injury". British Journal of Pharmacology. 122 (7): 1353–60. PMID 9421282.</ref>